- Phathom Pharmaceuticals (PHAT, Financial) to announce Q1 2025 financial results on May 1, 2025.
- Company to host live webcast at 8:00 am EDT with recording available for 90 days.
- Specializes in gastrointestinal treatments with products like VOQUEZNA® for GERD and H. pylori infections.
Phathom Pharmaceuticals, Inc. (PHAT), a biopharmaceutical company focused on gastrointestinal diseases, has scheduled the announcement of its first quarter 2025 financial results for Thursday, May 1, 2025. The company will also provide a business update during a live webcast at 8:00 am EDT. The webcast will be accessible via the company's investor relations website, and a recording will remain available for 90 days post-event.
Phathom Pharmaceuticals is known for developing and commercializing novel treatments, particularly in the United States. The company markets VOQUEZNA® (vonoprazan) tablets, which are used for the relief of heartburn associated with Non-Erosive GERD in adults, as well as for the healing and maintenance of Erosive GERD. Furthermore, VOQUEZNA® TRIPLE PAK® and DUAL PAK® are offered for the treatment of H. pylori infections.
The company invites interested parties to join the webcast to gain insight into its financial performance and strategic direction for the upcoming quarters. For further details and access to the event, visit the Phathom Pharmaceuticals website’s Events & Presentations section.
